FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000979583> ?p ?o ?g. }

• W2000979583 endingPage "260" @default.
• W2000979583 startingPage "249" @default.
• W2000979583 abstract "To better identify factors affecting prostate-specific antigen (PSA) level elevation after radical prostatectomy alone in men with clinical Stage T1-2 prostate cancer, we have reviewed our experience in the PSA era with 337 cases. The identification of these factors permits better understanding of the impact of case selection on treatment outcome in prostate cancer.The charts of all patients treated with radical prostatectomy alone between 1987 and 1993 were reviewed. Patients with clinical Stage T3 disease, without preoperative Gleason scores or PSA levels, with synchronous bladder cancer, and who received adjuvant or neoadjuvant therapy were excluded. The distribution of cases by pretreatment PSA levels was as follows: 4 ng/mL or less (16%); greater than 4 to 10 ng/mL (48%); greater than 10 to 20 ng/mL (22%); and greater than 20 ng/mL (14%). The median pretreatment PSA level for the entire group was 8 ng/mL. Only 26 patients (8%) had pathologically positive pelvic lymph nodes. The overall margin involvement rate was 43%. Margin involvement rates increased with increasing preoperative PSA levels. One hundred eighty-two patients (54%) had surgical Gleason scores of 7 or higher and 208 (62%) had extracapsular extension. The median follow-up time was 36 months.The 3- and 5-year relapse-free survival (RFS) rates were 74% and 61%, respectively, with relapse being defined as either a clinically detectable recurrence or detectable/rising PSA levels. Among preoperative factors, PSA level was the only independent factor predicting relapse (P = 0.006); the 5-year RFS was 89% in patients with preoperative PSA levels of 4 ng/mL or less; 62% for PSA level of 4 to 10 ng/mL; 56% for PSA level to 10 to 20 ng/mL; and 26% for a PSA level greater than 20 ng/mL. Among pathologic parameters, margin involvement was the most potent independent factor predicting relapse (P < 0.001), followed by Gleason score (P = 0.002) and capsular penetration (P = 0.006). The 5-year RFS rates for margin-positive versus margin-negative patients were 37% versus 80%, respectively (P < 0.001). With pretreatment PSA levels of 10 ng/mL or less, lymph node involvement was seen in 3%, and margin involvement in 36%; the 5-year RFS rate was 71%. With pretreatment PSA levels of greater than 10 ng/mL, lymph node involvement was seen in 16%, and margin involvement in 57%; the 5-year RFS rate was 42%. However, patients with an initial PSA level greater than 10 ng/mL and positive margins had a 5-year RFS rate of 22% versus 73% in patients with a PSA level of 10 ng/mL or less or negative margins (P < 0.001). All clinical relapses were accompanied by a rise in PSA. In patients manifesting a clinical recurrence, PSA elevations preceded clinical recurrences by an average of 15 months (range 0 to 71). Only 34 cases (10%) had clinical failures within 5 years.Pretreatment PSA is the most potent clinical factor independently predicting biochemical relapse. The great range in the relapse-free survival rates predicted by preoperative PSA levels demonstrates the importance of pretreatment PSA levels in case selection. Gleason score, extracapsular extension, and surgical margin involvement are also independent predictors of biochemical relapse. Achieving negative margins, even in relatively advanced disease, provides excellent long-term local control." @default.
• W2000979583 created "2016-06-24" @default.
• W2000979583 creator A5001069772 @default.
• W2000979583 creator A5024098067 @default.
• W2000979583 creator A5038790327 @default.
• W2000979583 creator A5057535320 @default.
• W2000979583 creator A5081391086 @default.
• W2000979583 date "1996-08-01" @default.
• W2000979583 modified "2023-09-23" @default.
• W2000979583 title "Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer" @default.
• W2000979583 cites W1414585854 @default.
• W2000979583 cites W165132104 @default.
• W2000979583 cites W190857994 @default.
• W2000979583 cites W1921045897 @default.
• W2000979583 cites W1978267162 @default.
• W2000979583 cites W1986356842 @default.
• W2000979583 cites W2050318104 @default.
• W2000979583 cites W2051236771 @default.
• W2000979583 cites W2053510778 @default.
• W2000979583 cites W2127095751 @default.
• W2000979583 cites W2222589758 @default.
• W2000979583 cites W2235954515 @default.
• W2000979583 cites W2312408681 @default.
• W2000979583 cites W2397717046 @default.
• W2000979583 cites W2399030910 @default.
• W2000979583 cites W2402217318 @default.
• W2000979583 cites W2408870408 @default.
• W2000979583 cites W2410181980 @default.
• W2000979583 cites W27466347 @default.
• W2000979583 cites W4293658047 @default.
• W2000979583 cites W58289321 @default.
• W2000979583 cites W66741530 @default.
• W2000979583 doi "https://doi.org/10.1016/s0090-4295(96)00167-7" @default.
• W2000979583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8753737" @default.
• W2000979583 hasPublicationYear "1996" @default.
• W2000979583 type Work @default.
• W2000979583 sameAs 2000979583 @default.
• W2000979583 citedByCount "195" @default.
• W2000979583 countsByYear W20009795832012 @default.
• W2000979583 countsByYear W20009795832013 @default.
• W2000979583 countsByYear W20009795832014 @default.
• W2000979583 countsByYear W20009795832015 @default.
• W2000979583 countsByYear W20009795832016 @default.
• W2000979583 countsByYear W20009795832018 @default.
• W2000979583 countsByYear W20009795832019 @default.
• W2000979583 countsByYear W20009795832020 @default.
• W2000979583 countsByYear W20009795832021 @default.
• W2000979583 countsByYear W20009795832022 @default.
• W2000979583 crossrefType "journal-article" @default.
• W2000979583 hasAuthorship W2000979583A5001069772 @default.
• W2000979583 hasAuthorship W2000979583A5024098067 @default.
• W2000979583 hasAuthorship W2000979583A5038790327 @default.
• W2000979583 hasAuthorship W2000979583A5057535320 @default.
• W2000979583 hasAuthorship W2000979583A5081391086 @default.
• W2000979583 hasConcept C121608353 @default.
• W2000979583 hasConcept C126322002 @default.
• W2000979583 hasConcept C126894567 @default.
• W2000979583 hasConcept C143998085 @default.
• W2000979583 hasConcept C146357865 @default.
• W2000979583 hasConcept C151730666 @default.
• W2000979583 hasConcept C2776235491 @default.
• W2000979583 hasConcept C2778913397 @default.
• W2000979583 hasConcept C2779466945 @default.
• W2000979583 hasConcept C2780192828 @default.
• W2000979583 hasConcept C2781406297 @default.
• W2000979583 hasConcept C71924100 @default.
• W2000979583 hasConcept C86803240 @default.
• W2000979583 hasConceptScore W2000979583C121608353 @default.
• W2000979583 hasConceptScore W2000979583C126322002 @default.
• W2000979583 hasConceptScore W2000979583C126894567 @default.
• W2000979583 hasConceptScore W2000979583C143998085 @default.
• W2000979583 hasConceptScore W2000979583C146357865 @default.
• W2000979583 hasConceptScore W2000979583C151730666 @default.
• W2000979583 hasConceptScore W2000979583C2776235491 @default.
• W2000979583 hasConceptScore W2000979583C2778913397 @default.
• W2000979583 hasConceptScore W2000979583C2779466945 @default.
• W2000979583 hasConceptScore W2000979583C2780192828 @default.
• W2000979583 hasConceptScore W2000979583C2781406297 @default.
• W2000979583 hasConceptScore W2000979583C71924100 @default.
• W2000979583 hasConceptScore W2000979583C86803240 @default.
• W2000979583 hasIssue "2" @default.
• W2000979583 hasLocation W20009795831 @default.
• W2000979583 hasLocation W20009795832 @default.
• W2000979583 hasOpenAccess W2000979583 @default.
• W2000979583 hasPrimaryLocation W20009795831 @default.
• W2000979583 hasRelatedWork W1967410728 @default.
• W2000979583 hasRelatedWork W1967788236 @default.
• W2000979583 hasRelatedWork W2038565121 @default.
• W2000979583 hasRelatedWork W2093197441 @default.
• W2000979583 hasRelatedWork W2101697404 @default.
• W2000979583 hasRelatedWork W2102254866 @default.
• W2000979583 hasRelatedWork W2402249956 @default.
• W2000979583 hasRelatedWork W2897445903 @default.
• W2000979583 hasRelatedWork W3150909901 @default.
• W2000979583 hasRelatedWork W4241710403 @default.
• W2000979583 hasVolume "48" @default.
• W2000979583 isParatext "false" @default.
• W2000979583 isRetracted "false" @default.

• next